(Circulation. 2000;101:2803.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From Medizinische Klinik und Poliklinik I, Universitätsklinikum Charité, Arbeitsgruppe Medizinische Biometrie, Humboldt-Universität zu Berlin, Berlin, Germany.
| Abstract |
|---|
|
|
|---|
Methods and ResultsWe investigated 142 CHF patients (mean NYHA
class, 2.6; mean maximum oxygen consumption
[
O2max], 15.3 mL O2
· kg-1 · min-1; mean left
ventricular ejection fraction [LVEF], 27%). Patients
were compared with 101 healthy control subjects.
Cardiopulmonary exercise testing was performed, and ventilatory
efficiency was defined as the slope of the linear relationship of
CO2 and ventilation (VE). Results
are presented in percent of age- and sex-adjusted mean values.
Forty-four events (37 deaths and 7 instances of heart transplantation,
cardiomyoplasty, or left ventricular assist device
implantation) occurred. Among
O2max,
NYHA class, LVEF, total lung capacity, and age, the most powerful
predictor of event-free survival was the VE versus
CO2 slope; patients with a slope
130%
of age- and sex-adjusted normal values had a significantly better
1-year event-free survival (88.3%) than patients with a slope >130%
(54.7%; P<0.001).
ConclusionsThe VE versus
CO2
slope is an excellent prognostic parameter. It is easier to
obtain than parameters of maximal exercise capacity and is
of higher prognostic importance than
O2max.
Key Words: prognosis heart failure ventilation
| Introduction |
|---|
|
|
|---|
O2max1 and
closely relates to symptomatology.2 3 Both NYHA class and
O2max have been proven to be
good predictors of prognosis in CHF. Therapy with ACE
inhibitors known to improve prognosis also betters
ventilatory efficiency.3 Ventilatory efficiency can be
derived from a moderate effort well before exhaustion and is highly
reproducible.1
Therefore, we investigated the impact of ventilatory efficiency in
CHF on outcome and compared it with other prognostic
parameters like left ventricular ejection
fraction (LVEF), NYHA class, and
O2max. To maximize the
physiological information from
cardiopulmonary exercise testing (CPX), we normalized
O2max and the slope of
ventilation (VE) versus
CO2
for age and sex using our own control population.4 5
| Methods |
|---|
|
|
|---|
Symptoms were attributed to heart and not lung disease in all patients,
albeit the mild abnormality of pulmonary function tests in some
patients was thought to be secondary to heart disease. Current smoking
status and smoking history are presented in Table 1
.
|
Origin and severity of CHF were determined by
echocardiography (n=130), chest radiograph (n=114),
or cardiac catheterization (n=95). Inclusion criteria
were a
O2max <25 mL
O2 · kg-1 ·
min-1 and either cardiothoracic ratio >0.5,
echocardiographic left ventricular
end-diastolic diameter
57 mm, or LVEF determined by
contrast ventriculography or echocardiography
45%. Mean LVEF was 27% (median, 26%). One hundred nineteen
patients were in sinus rhythm, 19 had atrial fibrillation, and 4 had
pacemaker rhythm.
Current medication included ACE inhibitors (89%), diuretics (69%), nitrates (67%), digitalis (52%), anticoagulants (30%), and antiarrhythmics (6%). Ten percent were on calcium antagonists, mainly for rate control, and 31% were on aspirin for coronary disease.
Control Subjects
One hundred one healthy volunteers 16 to 75 years of age (mean,
37±14 years) underwent CPX testing to establish age- and sex-corrected
normal values. Forty-five were female (weight, 60±8 kg; height, 165±6
cm), 56 were male (weight, 78±12 kg; height, 179±9 cm). Results have
been published in part elsewhere.4 Linear regression
analysis for age versus oxygen consumption and VE versus
CO2 slope revealed the
following mean normal value formulas: VE versus
CO2 slope: 0.13xage+19.9 for
men and 0.12xage+24.4 for women;
O2 at the gas exchange
anaerobic threshold
(
O2AT): -0.17xage+28.6 for
men and -0.16xage+24.2 for women;
O2max: -0.36xage+51.5 for
men and -0.34xage+44.6 for women.
For prognostic analysis, oxygen consumption and VE versus
CO2 slope values are
presented as percent predicted (PP) from the individual age-
and sex-corrected mean normal values.
Exercise Testing
In all patients and control subjects, a symptom-limited CPX test
was performed according to the modified Naughton protocol6
with a Medical Graphics CPX/D system. Details of our test protocol have
been published earlier.4
Great effort was undertaken not to stop exercise prematurely. However, indications to stop the test were a higher degree of AV block or ventricular tachycardia >5 consecutive beats at a rate >120/min, new atrial fibrillation, ST-segment depression >3 mm, or systolic blood pressure >260 mm Hg, as well as a progressive decrease in blood pressure.
O2max was defined as the peak
O2 measured, always occurring
well beyond the anaerobic threshold.
O2 at
O2AT was detected by the
V-slope method,7 8 supplemented by
simultaneous observation of end-tidal gas concentrations
(PETO2/CO2).
Ventilatory efficiency on exercise was measured by plotting VE against
CO2. This plot revealed a
linear relationship (r=0.98 to 0.99). The ventilatory
efficiency on exercise is represented by its slope. The
nonlinear part of this relationship after onset of acidotic drive to
ventilation8 was excluded.
Lung Function Tests
Routine lung function tests, including total lung capacity
(TLC), forced expiratory volume in 1 second
(FEV1), inspiratory vital capacity (IVC), and
diffusion capacity for carbon monoxide (DLCO), were
expressed as percent predicted of normal PP. Oxygen saturation was
continuously measured percutaneously by pulse oximetry
on the ear lobe. Breathing reserve was calculated as
100-(100xVEmax/resting
FEV1x41).9
Follow-Up Data on Prognosis
Follow-up events included overall deaths, cardiac
transplantation (HTX), implantation of a left ventricular
assist device (LVAD), or cardiomyoplasty. Most patients had a follow-up
of >1 year. Minimal follow-up was 6 months. One patient was lost to
follow-up.
Statistical Analysis
Results are presented as mean±SD. For comparison
between groups, the Mann-Whitney U test was used; to compare
prognostic parameters, linear and logistic regression
analyses were performed. Correlations were determined according
to Bravais-Pearson or Spearman. The follow-up data were
analyzed by Kaplan-Meier life-table analysis and the
log-rank test. To define the cutoffs giving the best discrimination in
defining the likelihood of event-free survival, univariate
log-rank tests (Mantel-Haenszel)10 were used. A
multiple Cox regression analysis was performed using LVEF,
O2max, VE versus
CO2 slope, age, TLC, and NYHA
class.11
Classification trees (CART) were constructed with subgroups internally as homogeneous and externally as heterogeneous as possible, measured on the corresponding log-rank test.12 13 The successive splits of the tree correspond to the features with the greatest prognostic importance. For diagnostic testing sensitivity, accuracy and ORs were estimated.
| Results |
|---|
|
|
|---|
O2AT and
O2max were 10.7±3.2 and
15.2±4.7 mL O2 ·
kg-1 · min-1
(median, 57 and 47 PP), respectively, in the patient group. The VE
versus
CO2 slope was
39.3±16.4 (median, 128 PP). There was no difference between the 2
major etiologic subgroups.
At termination of exercise, patients used 44±15% of maximal breathing
capacity; healthy volunteers, 59±12%. In patients and in all NYHA
subgroups,
O2max was reached
earlier after
O2AT than in
normal subjects
(
O2AT/
O2max
in patients, 71±11%; in normal subjects, 58±9%;
P<0.001; see Table 2
).
Termination of exercise because of angina or by the physician did not
influence the
O2AT/
O2max
ratio. Patients with normal and reduced ventilatory efficiency had
similar
O2AT/
O2max
ratios (71±11% versus 72±10%).
|
Oxygen Desaturation and Lung Function Testing
In 6 of 142 patients, a significant decrease in oxygen saturation
(
4%) was found (mean, 96% to 87%). Five of these were in NYHA
class III, and 1 was in class IV. One had a small atrial septum defect,
and 1 had suspected pulmonary embolism with extremely elevated
VE versus
CO2 slope (140)
normalized at reevaluation. The other 4 had severe CHF
(
O2AT, 4.7 to 9.0;
O2max, 6.1 to 11.2 mL
O2 · kg-1 ·
min-1; VE versus
CO2 slope, 57 to 85), and all
4 died within 2 years. Lung function and smoking status are given in
Table 1
.
Relationship Between Ventilatory Efficiency, Symptoms, and
Exercise Capacity
Ventilatory efficiency was impaired (VE versus
CO2 slope >35) in 46% of
patients. Patients with reduced ventilatory efficiency had lower LVEF
(20±7% versus 25±8%; P<0.001) and
O2max (12.2±3.6
versus 17.8±3.9; P<0.001) than patients without reduced
ventilatory efficiency.
Results in various NYHA classes are presented in Table 2
. The VE versus
CO2
slope but not
O2AT or
O2max was significantly
different in all NYHA classes (P<0.05), but the correlation
between VE versus
CO2 slope and NYHA
class was not very good (r=0.44; P<0.001).
Exercise ventilatory efficiency correlated with
O2AT
(r=-0.70, P<0.001),
O2max
(r=-0.70; P<0.001), and exercise time
(r=-0.53; P<0.001) but only weakly with LVEF
(r=-0.17; P=0.048).
The correlations between exercise capacity and ventilatory efficiency
were similar using the PP values
(VO2max PP and slope PP:
r=-0.64; P<0.001;
O2AT PP and slope
PP: r=0.65; P<0.001).
Follow-Up of Vital Status
Thirty-seven deaths occurred during follow-up. An additional 7
patients survived HTX, cardiomyoplasty, or LVAD implantation. Eight
deaths occurred at various time intervals after prior HTX, LVAD, or
cardiomyoplasty. Median event-free survival was 38 months (overall
survival, 39 months). Univariate Kaplan-Meier
analysis of event-free survival revealed significant survival
differences (log-rank test) with cutoff points for
O2AT at 10 mL ·
kg-1 · min-1 or
30, 45, and 50 PP;
O2max at
10, 12, and 14 mL · kg-1 ·
min-1 or 45 PP; and VE versus
CO2 slope at 35 and 40 L/L
CO2 or 125 and 130 PP.
Figure 1
shows the event-free survival
for the total group, and Figure 2a
and 2b
shows Kaplan-Meier life-table analyses (event-free survival)
for the best cutoffs, ie,
O2max (>45 versus
45 PP)
and VE versus
CO2 slope (
130
versus >130 PP). The best cutoff for
O2AT was >50 versus
50 PP
(life table not shown).
|
|
In a multivariate Cox regression analysis, the
following items were included: age, LVEF, NYHA class,
O2max, VE versus
CO2 slope, and TLC. The
analysis revealed the VE versus
CO2 slope to be the most
powerful predictor of event-free survival, followed by
O2max.
O2max did not substantially
improve the predictive value of the model. Classification trees were
used to estimate the practical usefulness of the model to predict
1-year overall and event-free survival. Of the 141 patients, 105 were
survivors of the first year of follow-up, and 103 survived without an
event. According to the best discriminating variable and cutoffs in
the log-rank statistics, we included the following
parameters/cutoffs in the CART analysis:
O2AT cutoff, 50 PP; VE versus
CO2 slope, 130 PP; NYHA
functional class, I/II versus III/IV and I to III versus IV;
O2max cutoff, 45 PP; age, 65
years; and LVEF, 25%. The VE versus
CO2 slope had by far the
highest log-rank test value (25.65; P<0.0001), followed by
O2max (with a
log-rank test value of 7.57; P=0.0059). The VE versus
CO2 slope was
therefore used as the first parameter to dichotomize the
patients. Analysis for event-free and overall survival revealed
essentially the same: both the VE versus
CO2 slope in PP and
the
O2max PP
represented important information for the prognosis.
Patients with a VE versus
CO2 slope
130 PP
had a significantly better 1-year event-free survival (88.3%) than
patients with a slope >130 PP who had a 1-year event-free survival of
only 54.7% (overall survival, 88.3% versus 57.8%).
Patients with a VE versus
CO2
slope >130 PP but a
O2max
>45 PP had a 79.2% 1-year event-free survival. No other
parameters were useful to further characterize the
prognosis of patients with a VE versus
CO2 slope
130 PP who had a
good prognosis. For details, see Figure 3
.
|
The sensitivity and specificity of a VE versus
CO2 slope with a cutoff of 130
PP for survival were 70.3% and 63.5%; positive and negative
predictive values were 40.6% and 85.7%, accuracy was 65.3%, the OR
was 4.1, and the 95% CI was 1.9 to 9.0.
| Discussion |
|---|
|
|
|---|
One of the most prominent features of dyspnea in CHF is hyperpnea, ie,
an increase in ventilation relative to gas exchange. It is caused by
early anaerobic metabolism, an increase in
anatomical dead space by increased breathing rate and
low tidal volumes caused by secondary restrictive physiology or
respiratory muscle fatigue,16 a decreased
PaCO2 set point resulting from
acidosis, disturbances of diffusion,17 activation
of muscle ergoreceptors,18 and respiratory muscle
deoxygenation.19 The most important cause
of hyperpnea, however, is the increase in
physiological dead space by alveolar
hypoperfusion20 21 Therefore, we investigated the
prognostic importance of ventilatory efficiency in patients with CHF
and compared it with other currently used prognostic
parameters like LVEF,22 23 NYHA
class,24 25 and
O2max.
Population Under Study
Patients suffered mainly from coronary disease or dilated
cardiomyopathy similar to recently reported
patients.26 All patients had an LVEF
45%; all NYHA I
patients had an LVEF <35%.
There was no difference in smoking status in patients with reduced
compared with normal ventilatory efficiency. Differences in
pulmonary function tests were small and thought to be secondary
to CHF. Lungs were somewhat smaller in patients with reduced
ventilatory efficiency, as has been shown in normal subjects under
exercise27 and in persons susceptible to high-altitude
pulmonary edema.28 This might contribute to
/
mismatch by making a small ventilation-perfusion
inequality more important. The slight decrease in TLC in our patients,
however, is unlikely to contribute to a larger extent to the decrease
in ventilatory efficiency. Forty-six percent of patients had reduced
ventilatory efficiency (median, 128 PP).
Similar to Veterans Administration Heart Failure Trial (V-HeFT)
findings,29 mean
O2max was 15.2 mL ·
kg-1 · min-1, and
cardiocirculatory limitation was confirmed by the high breathing
reserve at the end of exercise, low rate of oxygen desaturation, and
absence of pulmonary disease.
The lack of any important correlation to LVEF is not
unexpected,23 30 and an LVEF
30% might not give very
useful information regarding prognosis.14 31 More than
70% of our population had an LVEF
30%.
Follow-Up of Vital Status and CHF Events
Prognostic parameters in CHF24 include
symptoms,25 32 33 hemodynamics, LVEF,
cardiothoracic ratio,29 neurohormones,34 35
electrolytes,36 and
O2max.31 37 38 We
used
O2 PP derived from our
own large control population. Among LVEF, NYHA class, age, and TLC, the
VE versus
CO2 slope was the
most powerful indicator of prognosis in a multivariate
analysis.
VE/
CO2 ratio and slope are
known to correlate to
O2max.39 Our
results demonstrate that the VE versus
CO2 slope contains prognostic
information in addition to and beyond the measurement of
O2max: Patients with a VE
versus
CO2 slope >130 PP had
a 1-year mortality >40%, and even if
O2max were preserved, 1-year
mortality was >20%. Ventilatory efficiency is easier to obtain than
O2max and can be derived from
a submaximal exercise test. The high negative predictive value of a
normal ventilatory efficiency (ie, slope
130 PP) is of special
clinical relevance for patients with low
O2max or those who cannot
exercise until exhaustion.
Underlying Physiology and Study Limitations
This study lacks an explanation of how ventilatory efficiency
affects prognosis in CHF. Although normal ventilatory control in
CHF40 has been shown, an uncoupling of ventilation from
CO2 production41 has also
been reported and thought to be due to activation of muscle
ergoreceptors. However, substantial changes in arterial
CO2 tension have not been
found,40 42 43 and the changes in
physiological dead space suggested by increased
ventilation40 42 43 and near-normal
PCO2 would thus be secondary.
An alternative explanation is that the increase in physiological dead space is directly caused by alveolar hypoperfusion44 resulting from impaired endothelial vasodilatory capacity45 46 47 or neuroendocrine activation.35 48 If this theory is correct, the "muscle hypothesis" would not easily fit in.
A major diffusion disturbance17 49 is an unlikely explanation for the derangement of ventilatory efficiency because CO2 diffuses much more easily than oxygen and a decrease in oxygen saturation has not been found in >95% of our patients. It might become important in severe CHF with prominent congestion.
Another limitation of our study is that not all patients stopped
exercise for dyspnea or fatigue. This might introduce a considerable
error through ischemic pump dysfunction. However, the
reluctance to include patients with angina would not have reliably
excluded silent ischemia, nor would it be meaningful to
disregard some contribution of ischemia in a setting of CHF,
whose leading cause is ischemic heart disease. Furthermore,
dyspnea might be the only symptom of angina. Thus, in any exercise
testing of CHF patients, ischemia is likely to play some part.
The VE versus
CO2 relationship
should, on the contrary, be of special value in this population,
because it is measured well before the onset of angina or
ischemia. Furthermore, the exclusion of patients who stopped
exercise before the onset of dyspnea or fatigue led to a similar ratio
of
O2max/
O2AT.
This indicates that our patients did not stop because of angina;
rather, ischemia concurred with the limitation by CHF at the
end of exercise in some of them.
Despite these limitations, our results show that measurement of the VE versus VCO2 relationship offers a unique way of estimating the prognosis of patients with CHF. During preparation of this article, similar results have been obtained by an independent group.50 Given the possibility of therapeutic influences on ventilatory efficiency,3 this might also provide a useful tool to guide therapy, especially in severe CHF.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received September 14, 1999; revision received January 15, 2000; accepted January 25, 2000.
| References |
|---|
|
|
|---|
2. Kleber FX, Reindl I, Wernecke KD, et al. Dyspnea in heart failure. In: Wasserman K, ed. Exercise Gas Exchange in Heart Disease. Armonk, NY: Futura Publishing Co Inc; 1996:95107.
3. Reindl I, Kleber FX. Exertional hyperpnea in patients with chronic heart failure is a reversible cause of exercise intolerance. Basic Res Cardiol. 1996;91(suppl 1):3743.
4. Habedank D, Reindl I, Vietzke G, et al. Ventilatory efficiency and exercise tolerance in 101 healthy volunteers. Eur J Appl Physiol. 1998;77:421426.
5. Habedank D, Reindl I, Sonntag CF, et al. Ventilatory efficacy in healthy volunteers during cardiopulmonary exercise testing. Eur J Appl Physiol. 1994;69(suppl 3):14. Abstract.
6.
Weber KT, Kinasewitz GT, Janicki JS, et al. Oxygen
utilization and ventilation during exercise in patients with chronic
cardiac failure. Circulation. 1982;65:12131223.
7.
Beaver WL, Lamarra N, Wasserman K. Breath-by-breath
measurement of true alveolar gas exchange. J Appl
Physiol. 1981;51:16621675.
8. Wasserman K, Stringer WW, Casaburi R, et al. Determination of the anaerobic threshold by gas exchange: biochemical considerations, methodology and physiological effects. Z Kardiol. 1994;83(suppl III):112.
9. Miller WF, Scacci R, Gast LR. Laboratory Evaluation of Pulmonary Function. Philadelphia, Pa: JB Lippincott Co; 1987;300.
10. Wernecke K-D. Angewandte Statistik für die Praxis. Bonn, Germany: Addison Wesley Publishing Co; 1995.
11. Kalbfleisch J, Prentics RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons; 1980.
12. Wernecke K-D, Possinger K, Kalb G, et al. Validating classification trees. Biometrical J. 1998;40:9931005.
13. Hartung J. Statistik Lehr und Handbuch der angewandten Statistik. München, Germany: Oldenburg Verlag; 1993.
14. Rickenbacher PR, Trindade PT, Haywood GA, et al. Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival. J Am Coll Cardiol. 1996;27:11921197.[Abstract]
15. Borg GAV. Psychophysical basis of perceived exertion. Med Sci Sports Exerc. 1982;14:377381.[Medline] [Order article via Infotrieve]
16.
Witt C, Borges AC, Haake H, et al. Respiratory muscle
weakness and normal ventilatory drive in dilative
cardiomyopathy. Eur Heart J. 1997;18:13221328.
17.
Puri S, Baker BL, Oakley CM, et al. Increased
alveolar/capillary membrane resistance to gas transfer in patients with
chronic heart failure. Br Heart J. 1994;72:140144.
18. Clark AL, Piepoli M, Coats AJS. Evidence for skeletal and muscle metabolic receptors driving ventilation on exercise. Circulation. 1993;88(suppl I):I-415. Abstract.
19. Mancini DM, Ferraro N, Nazzaro D, et al. Respiratory muscle deoxygenation during exercise in patients with heart failure demonstrated with near-infrared spectroscopy. J Am Coll Cardiol. 1991;18:492498.[Abstract]
20. Reindl I, Wernecke KD, Opitz C, et al. Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction. Am Heart J. 1998;136:778785.[Medline] [Order article via Infotrieve]
21.
Buller NP, Poole-Wilson PA. Mechanisms of the increased
ventilatory response to exercise in patients with chronic heart
failure. Br Heart J. 1990;63:281283.
22. Higginbotham MB, Morris KG, Conn EH, et al. Determinants of variable exercise performance among patients with severe left ventricular dysfunction. Am J Cardiol. 1983;51:5260.[Medline] [Order article via Infotrieve]
23. Franciosa JA, Park M, Levine TB. Lack of correlation between exercise capacity and indexes of resting left ventricular performance in heart failure. Am J Cardiol. 1981;47:3339.[Medline] [Order article via Infotrieve]
24. Stevenson LW. Heart transplant centers: no longer the end of the road for heart failure. J Am Coll Cardiol. 1996;27:11981200.[Medline] [Order article via Infotrieve]
25. Di Salvo TG, Mathier M, Semigran MJ, et al. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol. 1995;25:11431153.[Abstract]
26. Cohn JN, Johnson G, Ziesche S, et al. A Comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure (V-HeFT II). N Engl J Med. 1991;325:303310.[Abstract]
27.
Hopkins SR, Gavin T, Siavakas N, et al. Effect of
prolonged, heavy exercise on pulmonary gas exchange in
athletes. J Appl Physiol. 1998;85:15231532.
28.
Podolsky A, Eldridge MW, Richardson RS, et al.
Exercise-induced VA/Q inequality in subjects with prior high-altitude
pulmonary edema. J Appl Physiol. 1996;81:922932.
29. Cohn JN, Johnson GR, Shabetai R, et al, for the V-HeFT VA Cooperative Studies Group. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure. Circulation. 1993;87(suppl VI):VI-5. Abstract.
30.
Cohn JN. The management of chronic heart failure.
N Engl J Med. 1996;335:490498.
31. Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol. 1996;27:345352.[Abstract]
32. Saxon LA, Stevenson WG, Middlekauf HR, et al. Predicting death from progressive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 1993;72:6265.[Medline] [Order article via Infotrieve]
33. Campana C, Gavazzi A, Berzuini C, et al. Predictors of prognosis in patients awaiting heart transplantation. J Heart Lung Transplant. 1993;12:756765.[Medline] [Order article via Infotrieve]
34. Rector TS, Olivari MT, Levine TB, et al. Predicting survival for an individual with congestive heart failure using the plasma norepinephrine concentration. Am Heart J. 1987;114:148152.[Medline] [Order article via Infotrieve]
35. Francis GS, Rector TS, Cohn JN. Sequential neurohormonal measurements in patients with congestive heart failure. Am Heart J. 1988;116:14641468.[Medline] [Order article via Infotrieve]
36.
Lee WH, Packer M. Prognostic importance of serum sodium
concentration and its modification by converting-enzyme inhibition in
patients with severe chronic heart failure. Circulation. 1986;73:257267.
37.
Mancini DM, Eisen H, Kussmaul W, et al. Value of peak
exercise oxygen consumption for optimal timing of cardiac
transplantation in ambulatory patients with heart failure.
Circulation. 1991;83:778786.
38. Stevenson LW. Role of exercise testing in the evaluation of candidates for cardiac transplantation. In: Wasserman K, ed. Exercise Gas Exchange in Heart Disease. Armonk, NY: Futura Publishing Co Inc; 1995:271286.
39.
Milani RV, Mehra MR, Reddy TK, et al.
Ventilation/carbon dioxide production ratio in early exercise
predicts poor functional capacity in congestive heart failure.
Heart. 1996;76:393396.
40.
Sullivan MJ, Higginbotham MB, Cobb FR. Increased
exercise ventilation in patients with chronic heart failure: intact
ventilatory control despite hemodynamic and ventilatory
abnormalities. Circulation. 1988;77:552559.
41. Clark AL, Poole-Wilson PA, Coats AJ. Relation between ventilation and carbon dioxide production in patients with chronic heart failure. J Am Coll Cardiol. 1992;20:13261332.[Abstract]
42. Franciosa JA, Leddy CL, Wilen M, et al. Relation between hemodynamic and ventilatory responses in determining exercise capacity in severe congestive heart failure. Am J Cardiol. 1984;53:127134.[Medline] [Order article via Infotrieve]
43. Raijfer SI, Nemanich JW, Schurman AJ, et al. Metabolic responses to exercise in patients with heart failure. Circulation. 1987;76(suppl VI):VI-46VI-53.
44. Myers J, Salleh A, Buchanan N, et al. Ventilatory mechanisms of exercise intolerance in chronic heart failure. Am Heart J. 1992;124:710718.[Medline] [Order article via Infotrieve]
45.
Cooper CJ, Landzberg MJ, Anderson TJ, et al. Role of
nitric oxide in the local regulation of pulmonary vascular
resistance in humans. Circulation. 1996;93:266271.
46.
Celermajer DS, Dollery C, Burch M, et al. Role of
endothelium in the maintenance of low
pulmonary vascular tone in normal children.
Circulation. 1994;89:20412044.
47. Kleber FX, Wensel R, Felix SB, et al. Acetylcholine causes dose dependent increase in pulmonary flow in patients with chronic heart failure and elevated pulmonary vascular resistance. Basic Res Cardiol. 1996;91:401405.[Medline] [Order article via Infotrieve]
48. Nicholls P, Onuoha GN, McDowell G, et al. Neuroendocrine changes in chronic heart failure. Basic Res Cardiol. 1996;91(suppl I):1320.
49.
Puri S, Baker BL, Dutka DP, et al. Reduced
alveolar-capillary membrane diffusing capacity in chronic heart
failure: its pathophysiological relevance and
relationship to exercise performance. Circulation. 1995;91:27692774.
50. Chua TP, Ponikowski P, Harrington D, et al. Clinical correlates and prognostic significance of the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol. 1997;29:15851590.[Abstract]
This article has been cited by other articles:
![]() |
R. Naeije and P. van de Borne Clinical relevance of autonomic nervous system disturbances in pulmonary arterial hypertension Eur. Respir. J., October 1, 2009; 34(4): 792 - 794. [Full Text] [PDF] |
||||
![]() |
P. Laveneziana, D. E. O'Donnell, D. Ofir, P. Agostoni, L. Padeletti, G. Ricciardi, P. Palange, R. Duranti, and G. Scano Effect of biventricular pacing on ventilatory and perceptual responses to exercise in patients with stable chronic heart failure J Appl Physiol, May 1, 2009; 106(5): 1574 - 1583. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Magri, M. Brioschi, C. Banfi, J. P. Schmid, P. Palermo, M. Contini, A. Apostolo, M. Bussotti, E. Tremoli, S. Sciomer, et al. Circulating Plasma Surfactant Protein Type B as Biological Marker of Alveolar-Capillary Barrier Damage in Chronic Heart Failure Circ Heart Fail, May 1, 2009; 2(3): 175 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Koch, C. Schaper, T. Ittermann, T. Spielhagen, M. Dorr, H. Volzke, C. F. Opitz, R. Ewert, and S. Glaser Reference values for cardiopulmonary exercise testing in healthy volunteers: the SHIP study Eur. Respir. J., February 1, 2009; 33(2): 389 - 397. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ukkonen, I. G. Burwash, W. Dafoe, R. A. de Kemp, H. Haddad, K. Yoshinaga, R. A. Davies, E. K. Gannon, J. N. DaSilva, and R. S.B. Beanlands Is ventilatory efficiency (VE/VCO2 slope) associated with right ventricular oxidative metabolism in patients with congestive heart failure? Eur J Heart Fail, November 1, 2008; 10(11): 1117 - 1122. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Fleg Improving Exercise Tolerance in Chronic Heart Failure: A Tale of Inspiration? J. Am. Coll. Cardiol., April 29, 2008; 51(17): 1672 - 1674. [Full Text] [PDF] |
||||
![]() |
L. Ingle, K. K. Witte, J. G.F. Cleland, and A. L. Clark Combining the ventilatory response to exercise and peak oxygen consumption is no better than peak oxygen consumption alone in predicting mortality in chronic heart failure Eur J Heart Fail, January 1, 2008; 10(1): 85 - 88. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Albouaini, M. Egred, A. Alahmar, and D. J. Wright Cardiopulmonary exercise testing and its application Postgrad. Med. J., November 1, 2007; 83(985): 675 - 682. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Albouaini, M Egred, A Alahmar, and D J Wright Cardiopulmonary exercise testing and its application Heart, October 1, 2007; 93(10): 1285 - 1292. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Jankowska, T. Witkowski, B. Ponikowska, K. Reczuch, L. Borodulin-Nadzieja, S. D. Anker, M. F. Piepoli, W. Banasiak, and P. Ponikowski Excessive ventilation during early phase of exercise: A new predictor of poor long-term outcome in patients with chronic heart failure Eur J Heart Fail, October 1, 2007; 9(10): 1024 - 1031. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guazzi, R. Raimondo, M. Vicenzi, R. Arena, C. Proserpio, S. Sarzi Braga, and R. Pedretti Exercise oscillatory ventilation may predict sudden cardiac death in heart failure patients. J. Am. Coll. Cardiol., July 24, 2007; 50(4): 299 - 308. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Arena, J. Myers, M. A. Williams, M. Gulati, P. Kligfield, G. J. Balady, E. Collins, and G. Fletcher Assessment of Functional Capacity in Clinical and Research Settings: A Scientific Statement From the American Heart Association Committee on Exercise, Rehabilitation, and Prevention of the Council on Clinical Cardiology and the Council on Cardiovascular Nursing Circulation, July 17, 2007; 116(3): 329 - 343. [Full Text] [PDF] |
||||
![]() |
K. Wasserman, X.-G. Sun, and J. E. Hansen Effect of Biventricular Pacing on the Exercise Pathophysiology of Heart Failure Chest, July 1, 2007; 132(1): 250 - 261. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Fraga, F. G. Franco, F. Roveda, L. N.J. de Matos, A. M.F.W. Braga, M. U.P.B. Rondon, D. R. Rotta, P. C. Brum, A. C.P. Barretto, H. R. Middlekauff, et al. Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol Eur J Heart Fail, June 1, 2007; 9(6-7): 630 - 636. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Metra, P. Ponikowski, K. Dickstein, J. J.V. McMurray, A. Gavazzi, C.-H. Bergh, A. G. Fraser, T. Jaarsma, A. Pitsis, P. Mohacsi, et al. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail, June 1, 2007; 9(6-7): 684 - 694. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Arena, J. Myers, J. Abella, M. A. Peberdy, D. Bensimhon, P. Chase, and M. Guazzi Development of a Ventilatory Classification System in Patients With Heart Failure Circulation, May 8, 2007; 115(18): 2410 - 2417. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Vazir, P.C. Hastings, M. Dayer, H.F. McIntyre, M.Y. Henein, P.A. Poole-Wilson, M.R. Cowie, M.J. Morrell, and A.K. Simonds A high prevalence of sleep disordered breathing in men with mild symptomatic chronic heart failure due to left ventricular systolic dysfunction Eur J Heart Fail, March 1, 2007; 9(3): 243 - 250. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Habedank, R. Ewert, M. Hummel, R. Wensel, R. Hetzer, and S. D. Anker Changes in exercise capacity, ventilation, and body weight following heart transplantation Eur J Heart Fail, March 1, 2007; 9(3): 310 - 316. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Milani, C. J. Lavie, M. R. Mehra, and H. O. Ventura Understanding the Basics of Cardiopulmonary Exercise Testing Mayo Clin. Proc., December 1, 2006; 81(12): 1603 - 1611. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Agostoni, M. Contini, A. Magini, A. Apostolo, G. Cattadori, M. Bussotti, F. Veglia, D. Andreini, and P. Palermo Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia Eur J Heart Fail, November 1, 2006; 8(7): 729 - 735. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Dimopoulos, D. O. Okonko, G.-P. Diller, C. S. Broberg, T. V. Salukhe, S. V. Babu-Narayan, W. Li, A. Uebing, S. Bayne, R. Wensel, et al. Abnormal Ventilatory Response to Exercise in Adults With Congenital Heart Disease Relates to Cyanosis and Predicts Survival Circulation, June 20, 2006; 113(24): 2796 - 2802. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. N. Nanas, J. N. Nanas, D. Ch. Sakellariou, S. K. Dimopoulos, S. G. Drakos, S. G. Kapsimalakou, C. A. Mpatziou, O. G. Papazachou, A. S. Dalianis, M. I. Anastasiou-Nana, et al. VE/VCO2 slope is associated with abnormal resting haemodynamics and is a predictor of long-term survival in chronic heart failure Eur J Heart Fail, June 1, 2006; 8(4): 420 - 427. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kindermann, B. Hennen, J. Jung, J. Geisel, M. Bohm, and G. Frohlig Biventricular Versus Conventional Right Ventricular Stimulation for Patients With Standard Pacing Indication and Left Ventricular Dysfunction: The Homburg Biventricular Pacing Evaluation (HOBIPACE) J. Am. Coll. Cardiol., May 16, 2006; 47(10): 1927 - 1937. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Davies, R. Wensel, P. Georgiadou, M. Cicoira, A. J.S. Coats, M. F. Piepoli, and D. P. Francis Enhanced prognostic value from cardiopulmonary exercise testing in chronic heart failure by non-linear analysis: oxygen uptake efficiency slope Eur. Heart J., March 2, 2006; 27(6): 684 - 690. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Regitz-Zagrosek, B. Hocher, M. Bettmann, M. Brede, K. Hadamek, C. Gerstner, H. B. Lehmkuhl, R. Hetzer, and L. Hein {alpha}2C-Adrenoceptor polymorphism is associated with improved event-free survival in patients with dilated cardiomyopathy Eur. Heart J., February 2, 2006; 27(4): 454 - 459. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Arena, J. Myers, J. Abella, and M. A. Peberdy Influence of Heart Failure Etiology on the Prognostic Value of Peak Oxygen Consumption and Minute Ventilation/Carbon Dioxide Production Slope Chest, October 1, 2005; 128(4): 2812 - 2817. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guazzi, G. Reina, G. Tumminello, and M. D. Guazzi Alveolar-capillary membrane conductance is the best pulmonary function correlate of exercise ventilation efficiency in heart failure patients Eur J Heart Fail, October 1, 2005; 7(6): 1017 - 1022. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. F. Opitz, R. Wensel, J. Winkler, M. Halank, L. Bruch, F.-X. Kleber, G. Hoffken, S. D. Anker, A. Negassa, S. B. Felix, et al. Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension Eur. Heart J., September 2, 2005; 26(18): 1895 - 1902. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Agostoni, M. Bianchi, A. Moraschi, P. Palermo, G. Cattadori, R. La Gioia, M. Bussotti, and K. Wasserman Work-rate affects cardiopulmonary exercise test results in heart failure Eur J Heart Fail, June 1, 2005; 7(4): 498 - 504. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wonisch, P. Lercher, D. Scherr, R. Maier, R. Pokan, P. Hofmann, and S. P. von Duvillard Influence of Permanent Right Ventricular Pacing on Cardiorespiratory Exercise Parameters in Chronic Heart Failure Patients With Implanted Cardioverter Defibrillators Chest, March 1, 2005; 127(3): 787 - 793. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Arzt, M. Schulz, R. Wensel, S. Montalvan, F. C. Blumberg, G. A. J. Riegger, and M. Pfeifer Nocturnal Continuous Positive Airway Pressure Improves Ventilatory Efficiency During Exercise in Patients With Chronic Heart Failure Chest, March 1, 2005; 127(3): 794 - 802. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Guazzi, G. Reina, G. Tumminello, and M. D. Guazzi Exercise ventilation inefficiency and cardiovascular mortality in heart failure: the critical independent prognostic value of the arterial CO2 partial pressure Eur. Heart J., March 1, 2005; 26(5): 472 - 480. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. Meyer, D. Lossnitzer, A. V. Kristen, A. M. Schoene, W. Kubler, H. A. Katus, and M. M. Borst Respiratory muscle dysfunction in idiopathic pulmonary arterial hypertension Eur. Respir. J., January 1, 2005; 25(1): 125 - 130. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Corra, A. Mezzani, E. Bosimini, and P. Giannuzzi Cardiopulmonary Exercise Testing and Prognosis in Chronic Heart Failure*: A Prognosticating Algorithm for the Individual Patient Chest, September 1, 2004; 126(3): 942 - 950. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. X. Kleber The predictive value of cardiorespiratory fitness Eur. Heart J., August 2, 2004; 25(16): 1374 - 1375. [Full Text] [PDF] |
||||
![]() |
H. T. Robertson, R. Pellegrino, D. Pini, J. Oreglia, S. DeVita, V. Brusasco, and P. Agostoni Exercise response after rapid intravenous infusion of saline in healthy humans J Appl Physiol, August 1, 2004; 97(2): 697 - 703. [Abstract] [Full Text] [PDF] |
||||
![]() |
F.X Kleber, P Waurick, and M Winterhalter CPET in heart failure Eur. Heart J. Suppl., August 1, 2004; 6(suppl_D): D1 - D4. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Lamp, J. Vogt, H. Schmidt, and D. Horstkotte Impact of cardiopulmonary exercise testing on patient selection for cardiac resynchronisation therapy Eur. Heart J. Suppl., August 1, 2004; 6(suppl_D): D5 - D9. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. V. Milani, C. J. Lavie, and M. R. Mehra Cardiopulmonary Exercise Testing: How Do We Differentiate the Cause of Dyspnea? Circulation, July 27, 2004; 110(4): e27 - e31. [Full Text] [PDF] |
||||
![]() |
P. Agostoni, G. Cattadori, M. Bianchi, and K. Wasserman Exercise-Induced Pulmonary Edema in Heart Failure Circulation, November 25, 2003; 108(21): 2666 - 2671. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wolk, B. D. Johnson, and V. K. Somers Leptin and the ventilatory response to exercise in heart failure J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1644 - 1649. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Arena, J. Myers, S. S. Aslam, E. B. Varughese, and M. A. Peberdy Technical Considerations Related to the Minute Ventilation/Carbon Dioxide Output Slope in Patients With Heart Failure Chest, August 1, 2003; 124(2): 720 - 727. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Sakurai, H Adachi, A Hasegawa, H Hoshizaki, S Oshima, K Taniguchi, and M Kurabayashi Brain natriuretic peptide facilitates severity classification of stable chronic heart failure with left ventricular dysfunction Heart, June 1, 2003; 89(6): 661 - 662. [Full Text] [PDF] |
||||
![]() |
M. Arzt, M. Harth, A. Luchner, F. Muders, S. R. Holmer, F. C. Blumberg, G. A.J. Riegger, and M. Pfeifer Enhanced Ventilatory Response to Exercise in Patients With Chronic Heart Failure and Central Sleep Apnea Circulation, April 22, 2003; 107(15): 1998 - 2003. [Abstract] [Full Text] [PDF] |
||||
![]() |
T Tomita, H Takaki, Y Hara, F Sakamaki, T Satoh, S Takagi, Y Yasumura, N Aihara, Y Goto, and K Sunagawa Attenuation of hypercapnic carbon dioxide chemosensitivity after postinfarction exercise training: possible contribution to the improvement in exercise hyperventilation Heart, April 1, 2003; 89(4): 404 - 410. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Varma, S. Sharma, S. Firoozi, W. J. McKenna, J.-C. Daubert, and Multisite Stimulation in Cardiomyopathy (MUSTIC) S Atriobiventricular pacing improves exercise capacity in patients with heart failure and intraventricular conduction delay J. Am. Coll. Cardiol., February 19, 2003; 41(4): 582 - 588. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Gitt, K. Wasserman, C. Kilkowski, T. Kleemann, A. Kilkowski, M. Bangert, S. Schneider, A. Schwarz, and J. Senges Exercise Anaerobic Threshold and Ventilatory Efficiency Identify Heart Failure Patients for High Risk of Early Death Circulation, December 10, 2002; 106(24): 3079 - 3084. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Agostoni, M. Guazzi, M. Bussotti, S. De Vita, and P. Palermo Carvedilol Reduces the Inappropriate Increase of Ventilation During Exercise in Heart Failure Patients Chest, December 1, 2002; 122(6): 2062 - 2067. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-G. Sun, J. E. Hansen, N. Garatachea, T. W. Storer, and K. Wasserman Ventilatory Efficiency during Exercise in Healthy Subjects Am. J. Respir. Crit. Care Med., December 1, 2002; 166(11): 1443 - 1448. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Mejhert, E Linder-Klingsell, M Edner, T Kahan, and H Persson Ventilatory variables are strong prognostic markers in elderly patients with heart failure Heart, September 1, 2002; 88(3): 239 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
D.P. Nicholls, C. O'Dochartaigh, and M.S. Riley Circulatory power--a new perspective on an old friend Eur. Heart J., August 2, 2002; 23(16): 1242 - 1245. [PDF] |
||||
![]() |
R. Wensel, C. F. Opitz, S. D. Anker, J. Winkler, G. Hoffken, F. X. Kleber, R. Sharma, M. Hummel, R. Hetzer, and R. Ewert Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing Circulation, July 16, 2002; 106(3): 319 - 324. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-G. Sun, J. E. Hansen, R. J. Oudiz, and K. Wasserman Gas Exchange Detection of Exercise-Induced Right-to-Left Shunt in Patients With Primary Pulmonary Hypertension Circulation, January 1, 2002; 105(1): 54 - 60. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zugck, C. Kruger, R. Kell, S. Korber, D. Schellberg, W. Kubler, and M. Haass Risk stratification in middle-aged patients with congestive heart failure: prospective comparison of the Heart Failure Survival Score (HFSS) and a simplified two-variable model Eur J Heart Fail, October 1, 2001; 3(5): 577 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C.W. Hsia Coordinated Adaptation of Oxygen Transport in Cardiopulmonary Disease Circulation, August 21, 2001; 104(8): 963 - 969. [Full Text] [PDF] |
||||
![]() |
P. Ponikowski, T. P. Chua, S. D. Anker, D. P. Francis, W. Doehner, W. Banasiak, P. A. Poole-Wilson, M. F. Piepoli, and A. J.S. Coats Peripheral Chemoreceptor Hypersensitivity: An Ominous Sign in Patients With Chronic Heart Failure Circulation, July 31, 2001; 104(5): 544 - 549. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-G. Sun, J. E. Hansen, R. J. Oudiz, and K. Wasserman Exercise Pathophysiology in Patients With Primary Pulmonary Hypertension Circulation, July 24, 2001; 104(4): 429 - 435. [Abstract] [Full Text] [PDF] |
||||
![]() |
L TAVAZZI and P GIANNUZZI Physical training as a therapeutic measure in chronic heart failure: time for recommendations Heart, July 1, 2001; 86(1): 7 - 11. [Full Text] [PDF] |
||||
![]() |
D P Francis, L C Davies, and A J S Coats Diagnostic exercise physiology in chronic heart failure Heart, July 1, 2001; 86(1): 17 - 20. [Full Text] [PDF] |
||||
![]() |
A. L. Clark, F. X. Kleber, G. Vietzke, K.-D. Wernecke, U. Bauer, C. Opitz, R. Wensel, A. Sperfeld, and S. Glaser Impairment of Ventilatory Efficiency in Heart Failure Response Circulation, May 8, 2001; 103 (18): e97 - e97. [Full Text] [PDF] |
||||
![]() |
R. L. Johnson Jr Gas Exchange Efficiency in Congestive Heart Failure II Circulation, February 20, 2001; 103(7): 916 - 918. [Full Text] [PDF] |
||||
![]() |
R. L. Johnson Jr Gas Exchange Efficiency in Congestive Heart Failure Circulation, June 20, 2000; 101(24): 2774 - 2776. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |